Protein glycosylation has received much attention due to its multiple functional roles in physiological and pathophysiological conditions. Paucimannose is a common mannosidic N-glycoepitope in invertebrates and plants but has only recently been detected in vertebrates. Herein, we demonstrate the presence of paucimannosidic epitopes specifically in early postnatal neural progenitor cells (NPCs) between postnatal day 0 and 7 in mouse brain suggesting a possible role in the development of NPCs. Paucimannosidic epitopes were also detected in human glioblastoma cells and human macrophages by immunofluorescence and mass spectrometric analysis. Its expression was significantly increased after proliferation arrest indicating its importance in the regulation of cell proliferation. This hypothesis was further strengthened by reduced cell proliferation after the application of paucimannose-reactive Mannitou antibody into culture medium of growing cells. Most interestingly, this reduction in cell proliferation upon the administration of Mannitou antibody could also be observed in vivo in the subventricular zone of early postnatal mouse brain. Taken together, these observations demonstrate that paucimannosylation directly influences cell proliferation in various vertebrate cell types including early postnatal neural stem cells.
Introduction
It has become evident during the last years that protein glycosylation has regulatory effects during development, at different stages of cellular differentiation and aging. Furthermore, protein glycosylation plays important roles in diseases like diabetes, neurodegenerative disorders and cancer (Varki et al. 2009). Paucimannose is N-glycosidically attached to proteins and consists of two N-acetylglucosamine, 1-3 mannose residues and the option of a single fucose residue (mannose 1-3 fucose 0-1 N-acetylglucosamine 2 ; Schachter 2009 ). Previously, paucimannose was considered as an invertebrate-and plant-specific glycan. However, recently, it could be demonstrated that paucimannosidic glycans are expressed in vertebrates in some pathophysiological conditions such as cancer (Lattova et al. 2010; Balog et al. 2012; Zipser et al. 2012) , in systemic lupus erythematosus of mice (Hashii et al. 2009 ) and in sputum from the infected human lungs but also physiologically in adult pancreatic stem cells (Zipser et al. 2012) , in human buccal epithelial cells (Everest-Dass et al. 2012) , in rat brain tissue (Parker et al. 2013 ) and in differentiated neurospheres from embryonic neural stem cells (Yagi et al. 2012) . The latter results support other studies demonstrating alterations in protein glycosylation during differentiation of stem cells indicating a functional role of glycosidic epitopes in the cellular differentiation process (Dodla et al. 2011; Nourse et al. 2014) .
Two regions have been identified in rodent brain to produce new, functional neurons generated from stem cells throughout lifetime. These regions are the subventricular zone (SVZ) of the lateral ventricle (LV) and the subgranular zone (SGZ) in the dentate gyrus of the hippocampus (Ihrie and Alvarez-Buylla 2008) . Stem cells of embryonic and early postnatal mouse brain in the SVZ are radial glia cells that line the ventricular wall. They are capable of generating different neural cell types including SVZ astrocytes (type B cells) which represent SVZ stem cells of adult brain (Merkle et al. 2004) . SVZ astrocytes generate transit amplifying type C cells that give rise to type A cells which have the property to migrate through the rostral migratory stream (RMS) to the olfactory bulb (OB). Radial glia cells, type B, C and A cells are the main neural progenitor cell (NPC) types in the early postnatal SVZ (Doetsch et al. 1997) . After having reached their final destination in the OB, they integrate into different layers of the OB and differentiate into mature, functional neurons (Luskin 1998; AlvarezBuylla and Garcia-Verdugo 2002) .The diversity of postnatally generated neurons and their integration into functional neuronal circuits strongly suggest that they contribute in large part to adult brain plasticity. Therefore and since adult NPCs hold high promise for repair resulting from neurodegenerative diseases or brain trauma, adult neurogenesis especially in the SVZ has attracted much attention.
In this study, using the monoclonal Mannitou antibody that is highly specific for the trimannosidic paucimannose structure (Zipser et al. 2012) , we found that paucimannose is specifically expressed in early postnatal NPCs of mouse brain. Quantitative immunofluorescence and mass spectrometry (MS) analyses of paucimannosidic glycoepitopes of cultures of human glioblastoma cells and macrophages confirmed the presence of paucimannose in vitro and showed that its expression depends on the proliferation state of cells. Importantly, Mannitou antibody was shown to inhibit the proliferation of NPCs in vivo supporting the involvement of paucimannosylation in neural development in vertebrates.
Results

Paucimannosidic epitopes are expressed in the SVZ of mouse brain
Previously, it was reported that paucimannose is present in pancreatic exocrine duct cells (Zipser et al. 2012) , a region containing adult stem cells with the potential to generate β-cells (Reichert and Rustgi 2011) . Since we are interested in the development of postnatal neural stem cells, we investigated paucimannose levels in early developmental stages of mouse brains between postnatal day 0 (P0) and P10. Different brain regions were analyzed: the SVZ consisting of a specialized subset of progenitors including radial glia cells that represent the stem cells of embryonic and early postnatal mouse brain, and their progeny; the OB, containing NPCs that have migrated from the SVZ through the RMS to the OB; and the SGZ of the hippocampus. We found specific expression of paucimannosidic epitopes in the SVZ at the LV, in the RMS and in the center of the OB indicating the presence of paucimannose in NPCs of the SVZ (Figure 1 ) indicating its presence in radial glia cells and in NPCs generated from radial glia cells. No paucimannosidic epitopes were detectable in the SGZ of the dentate gyrus, the other neurogenic niche. Only cells localized dorsally of the hippocampus specifically expressed paucimannose (Figure 1, first row) .
These cells represent the rostrally located SVZ cells. Furthermore, paucimannose was not only regionally but also temporally restricted. Paucimannosylation was only detected in mouse brains between stage P0 and P7 (Figure 1 ; Supplementary data, Figures S1 and S2). Expression decreased at P7 and was only visible in the SVZ but not in cells that had migrated toward the OB. At P10, no paucimannosidic glycoepitopes were detected at all ( Figure 1 ). As control, Mannitou was preabsorbed with α-methyl mannoside which completely abolished specific staining by epitope competition thereby emphasizing its specific binding to paucimannose in postnatal mouse brains.
Proliferation arrest and cell differentiation increases paucimannosylation in cultured human cells
The particular presence of paucimannose in NPCs of the SVZ and in cancer tissue of vertebrates (Lattova et al. 2010; Balog et al. 2012; Yagi et al. 2012; Zipser et al. 2012) lead us to hypothesize that paucimannose may be involved in cell proliferation. To investigate this glycoepitope in more detail and its possible physiological role, cell culture studies were performed. From several neural cell lines tested in preliminary experiments, only A172 human glioblastoma cells displayed appreciable paucimannosylation and were chosen for further studies. Since A172 is a cell line derived from astrocytes that also mediate immune responses of the nervous system, a second non-neural human monocytic cell line (Thp-1) was also included in some of the subsequent experiments.
First, the level of paucimannosidic epitopes was examined in proliferating cells and in cells that were treated with cytosine β-D-arabinofuranoside (AraC) for proliferation arrest. Interestingly, A172 cells that were cultured for 3 or 5 days in the presence of AraC exhibited a significantly increased percentage of paucimannose-positive cells of 59.6 ± 5% (3 days, 10 µM AraC) compared with 16.7 ± 3.3% in the control (3 days) or of 68.0 ± 5.4% (5 days, 10 µM AraC) compared with 11.7 ± 2.3% (5 days, control). Results with 2 µM AraC were comparable with the results with 10 µM AraC ( Figure 2B ). Furthermore, the intensity of Mannitou staining per cell also increased significantly after AraC treatment from 8660 ± 1377 pixel/cell (100 ± 15.9%) in the control to 17,227 ± 2583 pixel/cell in 10 µM AraC-treated cells (corresponding to 198.7 ± 29.8%, Figure 2C ). Likewise, the AraC treatment of Thp-1 cells significantly increased the percentage of paucimannose-positive cells (59.5 ± 4.5%) compared with controltreated proliferating cells (28.0 ± 3.4%, Figure 2B ). Mannitou fluorescence intensity per cell also revealed a significant increase to 19,058 ± 485 pixel/cell (corresponding to 208.6 ± 5.3%) compared with 9137 ± 256 pixel/cell (100 ± 2.8%) in the control condition ( Figure 2C ). These results may point to a regulatory role of paucimannosidic epitopes in cell proliferation, although the possibility that the observed increase in paucimannose fluorescence could be a consequence of the cell cycle arrest should not be neglected. However, since paucimannosylation was in vivo found to be a signature of NPCs in early postnatal stages and was not detectable in later stages, a decrease rather than an increase in paucimannosylation following proliferation arrest was expected.
Next, we determined whether the level of paucimannosidic epitopes correlates not only with proliferation arrest but also with the differentiation state, since proliferation is often reciprocally correlated with cell differentiation. A172 cells were differentiated into more mature glia cells, Thp-1 cells into macrophages, respectively (Sakai et al. 1996; Takashiba et al. 1999) . Differentiated A172 cells showed a significant increase in the percentage of paucimannose-positive cells from 31.9 ± 2.0 to 51.5 ± 2.2%. A significant increase in the percentage of paucimannose-positive Thp-1 cells could also be observed after differentiation from 87.4 ± 3 to 97.5 ± 0.7% ( Figure 2D ). However, no significant difference in the intensity of paucimannosidic epitopes per cell was observed between the different conditions in A172 and Thp-1 cells (data not shown).
The presence of paucimannosidic epitopes derived from AraCtreated A172 cells was verified using liquid chromatography tandem MS (LC-MS/MS) analysis (Jensen et al. 2012) . Several paucimannosidic structures including the Mannitou reactive trimannosyl M3 (mannose 3 N-acetylglucosamine 2 ) glycan were identified in total cell lysates (12.2 ± 4.9% of the total N-glycome) and in the microsomal fraction (4.3 ± 0.8%, Figure 3A , Supplementary data, Figure S3 ), indicating paucimannose-epitopes on intracellular and membraneassociated proteins. To further investigate whether paucimannosidic epitopes are also present on the cell surface membrane, an immunofluorescence analysis without permeabilization was performed.
Compared with total paucimannose staining with permeabilization, a weaker signal was observed without permeabilization demonstrating its presence also on cell surface proteins ( Figure 3B ).
Paucimannosidic glycoepitopes partially co-localize with hexosaminidase A in vitro Next, the generation and subcellular localization of paucimannosidic glycoepitopes were investigated. Since paucimannose can be generated by hexosaminidase A (HexA) in vitro from more elongated structures (Moriguchi et al. 2007; Thaysen-Andersen et al. 2015) , a possible co-localization of HexA with paucimannosidic epitopes was studied. Indeed, a partial co-localization of paucimannose and HexA was detected (Figure 4) , suggesting a potential generation of paucimannosidic glycans by HexA also in A172 and Thp-1 cells. Since HexA is usually reported to be located in lysosomes, the and Cy3-conjugated secondary antibodies (red). Additionally, Mannitou was preincubated with α-methyl mannoside (Met-Mann) as a control for specificity before incubation with mouse brain sections. Nuclei were counterstained with Hoechst 33258. Specific paucimannose staining could be observed in the SVZ, the RMS and the OB at P0. No specific paucimannose staining was detectable at P10, bar represents 200 µm; DG, dentate gyrus; HIP, hippocampus. This figure is available in black and white in print and in color at Glycobiology online. AraC for 3 or 5 days, respectively, before immunofluorescence analysis was performed. Thp-1 cells (right panel) were cultured for 3 days in the presence or the absence of 10 µM AraC. Cell nuclei were counterstained with Hoechst 33258. The number of paucimannose-positive cells was counted and referred to the total cell number. At least 10 images from three independent experiments were analyzed, data are presented as the mean ± SEM, ***P < 0.001. (C) A172 or Thp-1 cells were cultured for 3 days in the presence or the absence of 10 µM AraC, respectively. Paucimannose-positive cells were analyzed for fluorescence intensity using Image J software. At least 10 images from three independent experiments were analyzed, data are presented as the mean ± SEM, ***P < 0.001, **P < 0.005. (D) Differentiation of A172 cells was induced by cyclic AMP (cAMP) and theophylline or by 12-myristate 13-acetate in Thp-1 cells. Visualization of paucimannose was performed with Mannitou and Cy2-conjugated secondary antibodies. Paucimannose-positive cells were counted and referred to the total cell number visualized by staining nuclei with Hoechst 33258. At least 10 images from three independent experiments were analyzed, data are given as the mean ± SEM, ***P < 0.001, *P < 0.05. This figure is available in black and white in print and in color at Glycobiology online.
presence of paucimannose in lysosomes was tested. Surprisingly, paucimannosidic epitopes were only marginally detected in lysosomes in neural cells, indicating that it is not generated by lysosomal degradation. Additionally, paucimannose could also only rarely be detected in endoplasmic reticulum (ER), Golgi compartments and endosomes derived from the Golgi apparatus (Supplementary data, Figure S4 ). To furthermore exclude the internalization of paucimannosidic proteins from the environment, localization of paucimannose in Rab5-positive early endosomes and Rab4-or Rab11-positive recycling endosomes were investigated. Paucimannose was also rarely present in these types of vesicles excluding a major uptake from the environment by endocytic processes and intracellular recycling (Supplementary data, Figure S5 ).
Paucimannosylation is functionally involved in proliferation/differentiation in vitro and in vivo in NPCs
Our data and previously published results strengthen the hypothesis that paucimannosylation is involved in the regulation of cell proliferation in vertebrates. To investigate whether paucimannose is functionally implicated in cell proliferation/differentiation, Mannitou was added to cell culture media of A172 cells and proliferation was analyzed based on the expression of Ki67 in nuclei of proliferating cells. It is commonly accepted that some antibodies have the ability to modify their epitope function (e.g. Cheresh 1987; Wayner et al. 1993; The relative distribution of the individual paucimannosidic N-glycan species in % of the entire N-glycome. Nomenclature and schematic presentation of the monosaccharides are according to the Consortium for Functional Glycomics, data are given as the mean ± SD. (B) A172 cells were cultured in the presence or the absence of AraC (10 µM, 3 days). Cells were fixed and permeabilized (P) or fixed without permeabilization (NP). Paucimannosidic epitopes were visualized with Mannitou and Cy2-conjugated secondary antibodies (green), nuclei were counterstained with Hoechst 33258, bar represents 50 µm. As a negative control (N), immunofluorescence was performed with blocking solution instead of Mannitou and Cy2-conjugated secondary antibodies. All images were taken using the same exposure time. This figure is available in black and white in print and in color at Glycobiology online. Fig. 4 . Paucimannose partially co-localizes with HexA. A172 or Thp-1 cells were cultured for 3 days. Cells were then processed for immunofluorescence and co-stained with Mannitou and anti-HexA antibodies, respectively. Paucimannose was visualized with Cy2-conjugated secondary antibodies, HexA using Cy3-conjugated secondary antibodies. Images were taken using an LSM510 MetaUV confocal microscope; bar represents 10 µm. The second and the fourth row (left side), respectively, show the profiles of co-localizations in A172 or Thp-1 cells which are highlighted in the right picture by the white lanes. Arrowheads in the images on the right side show overlap of Cy3 and Cy2 fluorescence. This figure is available in black and white in print and in color at Glycobiology online. Schmid et al. 1999; Kumar et al. 2000) . H28 antibody in the media served as a control to exclude unspecific immunoglobulin (Ig)-dependent effects. Interestingly, Mannitou significantly decreased proliferation of A172 cells compared with non-treated cells and H28 antibody-treated cells ( Figure 5A ). To exclude an effect on cell survival by Mannitou treatment, a cell viability assay was performed. Using Calcein acetoxymethylester (AM)/ethidium homodimer fluorometric detection, no significant difference in cell viability between control and Mannitou-treated cells could be observed (2.7 ± 0.7% dead cells in the control compared with 2.1 ± 0.4% in Mannitou-treated cells). In contrast, cell death initiation by methanol increased the percentage of dead cells to 12.2 ± 1.9%. Colorimetric detection by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) confirmed that cell viability is not affected by the Mannitou application ( Figure 5B ).
Next, we aimed to identify the inhibitory mechanism of Mannitou on cell proliferation. Mannitou was added to the cell culture media and immunofluorescence staining was performed without additional application of Mannitou after fixation and permeabilization of A172 cells. Detection with specific secondary antibodies revealed that Mannitou was incorporated into live A172 cells and its staining was comparable with that of paucimannose ( Figure 5C ) confirming the existence of paucimannosidic epitopes at the cell surface. The inhibitory effect of Mannitou might therefore be attributable to downregulation or blocking of paucimannosidic epitopes at the cell surface. However, an intracellular action of Mannitou after its internalization cannot be excluded.
To investigate whether paucimannose is also functionally involved in the proliferation of postnatal NPCs in the SVZ in vivo, we coinjected purified Mannitou together with enhanced green fluorescent protein (eGFP) expression plasmids into the LV of P1 mouse pups. Simultaneously, electroporation was performed to track the morphology and fate of SVZ stem cells as visualized by eGFP expression. This method has earlier been used to target specifically radial glia cells of neonatal mice, allows the direct observation of morphological differences in the SVZ and has successfully been applied for the quantification of different cell types in the SVZ (Barnabé-Heider et al. 2008; Boutin et al. 2008 Boutin et al. , 2009 ). We found a reduced number of GFP-positive cells and specifically of NPCs excluding radial glia cells 2 days after injection/electroporation compared with control injected cells further indicating the involvement of Mannitou in cell proliferation ( Figure 6 ). However, this result is in excellent agreement with our in vitro-based results which strongly suggest that paucimannosidic glycoepitopes are important for the regulation of cellular proliferation which can be modulated by Mannitou.
Discussion
Paucimannosylation in NPCs of the SVZ
One major finding of our study is the identification of specific paucimannosidic epitopes in early postnatal NPCs of mouse brains. Interestingly, paucimannosylation was found to be exclusively present in the SVZ and SVZ-derived cells between P0 and P7 and completely absent at P10. Paucimannosylation was still visible in the SVZ at P7 but was diminished in the RMS and the OB. It is accepted that at this developmental stage radial glia cells disappear and give rise to adult neural stem cells, the SVZ astrocytes (Merkle et al. 2004 ). Therefore, this stage marks the transformation from embryonic to adult stem cells. Our results and other studies indicate that specific protein glycosylation patterns may determine a variety of stem cell features. It is imaginable that paucimannosidic glycoepitopes are implicated in ongoing proliferation of early postnatal stem cells. The presence of specific glycans has earlier been suggested to play a functional role in cell proliferation of embryonic stem cells (Yagi et al. 2010) . Interestingly, a recent study demonstrated a direct involvement of specific N-glycans in the regulation of cell proliferation, showing prominent expression of Lewis X epitopes in undifferentiated neural stem cells in vitro and significant presentation of paucimannosidic glycans upon differentiation (Yagi et al. 2012) . Similarly, up-regulation of paucimannosylation was observed during differentiation of human embryonic stem cells (Satomaa et al. 2009 ). Unexpectedly, in our study, paucimannosidic epitopes are down-regulated during the differentiation process. One possibility for this discrepancy could be the different developmental cell stages analyzed and culture conditions. Previous studies targeted embryonic stages and analyzed glycans in vitro (Satomaa et al. 2009; Yagi et al. 2012) , whereas we investigated postnatal instead of embryonic cells and the differentiation process was traced in vivo. Furthermore, we demonstrated in vivo that Mannitou decreases the number of early postnatal NPCs, albeit cell survival during these experiments was not investigated. However, since our in vitro studies clearly indicate an effect on cell proliferation without loss of cell viability, it is likely that Mannitou has also no effect on cell survival in vivo but rather on cell proliferation. Mannitou probably affects the progeny of radial glia cells rather than radial glia cells themselves, since their number remained unchanged between control and Mannitou-injected mouse brains. How can this be explained? Although plasmid DNA exclusively targets radial glia cells during the electroporation process (Boutin et al. 2008) , the co-injected antibody may diffuse into the SVZ and target the progeny of radial glia cells. Diffusion of an administered antibody from the LV into deeper layers was demonstrated in embryonic mouse brains supporting this hypothesis (Loulier et al. 2009 ). Mannitou may otherwise regulate asymmetric cell division of radial glia cells thus generating a reduced number of progeny cells. At present, no evidence for a direct role of glycosylation in regulating asymmetric cell division can be found in the literature. However, several studies demonstrated a regulatory role of Notch signaling in the asymmetric cell division (Berdnik et al. 2002; Egger et al. 2010; Bhat et al. 2011; Tio et al. 2011) . Interestingly, Notch signaling has been connected to Lewis X epitope presence which is inversely regulated to paucimannosidic epitopes in NPCs (Yagi et al. 2012) , providing a possible link between paucimannosylation and asymmetric cell division.
Implication of paucimannosylation in proliferation/ differentiation
Mannitou was also shown to affect cell proliferation in cell cultures in vitro in agreement with our in vivo data on NPCs. By tracing the cellular fate of Mannitou, we showed that Mannitou was internalized by A172 cells implicating a cell surface receptor, i.e. paucimannoseepitopes to which the antibody can bind. Consistently, the existence of paucimannosidic glycoepitopes albeit at low levels at the cell surface of a panel of human breast epithelial cells was recently shown . Immunofluorescence analysis of non-permeabilized A172 cells and LC-MS/MS-based glycome profiling confirmed the presence of paucimannosidic N-glycans on (cell surface) membrane proteins. Since it is most likely that many proteins are paucimannosylated the observed reduced cell number is probably attributable to altered activity of several proteins in the presence of Mannitou resulting in a decreased cell proliferation an aspect that will be analyzed in the future. Detailed analysis of paucimannose at the cellular level was performed in vitro. Surprisingly, paucimannosidic epitopes increased significantly upon proliferation arrest. Regarding our in vivo data and previous studies showing an increase in paucimannosidic glycans in cancer tissues rather a decrease in paucimannosidic epitopes was expected (Lattova et al. 2010; Balog et al. 2012) . Supporting our data, N-glycan profiling of various colon cancer cell lines with different metastatic/aggressive properties revealed the highest paucimannose level in the cell line with the slowest doubling rate (Sethi et al. 2014) .
Since paucimannose has only recently been described in vertebrates, it is so far unknown which protein(s) carry paucimannosidic epitopes in A172 cells. Additionally, it has also not completely been clarified which enzyme(s) generate the paucimannosidic structures. In analogy to the invertebrate system, it has been speculated that also in vertebrates paucimannosidic structures are generated by HexA (Moriguchi et al. 2007; Schachter 2009 ) which is usually found in lysosomes of cells. We observed a partial co-localization of paucimannose with HexA but only little lysosomal-associated paucimannose indicating that paucimannose may arise from HexA action outside of lysosomes. Interestingly, paucimannosidic epitopes were also generated by HexA in azurophilic granules of human neutrophils and non-lysosomal localization and activity of HexA was shown earlier in plasma membranes of fibroblasts (Mencarelli et al. 2005) . The spatial expression of HexA and functional analysis of paucimannose generation needs further investigation to understand the exact mechanisms of paucimannose synthesis.
In agreement with an increase in paucimannose upon proliferation arrest differentiation also significantly increased paucimannosepositive cells strengthening the involvement of paucimannose in the regulation of cell proliferation and hence differentiation.
Subcellular localization of paucimannose
The identification of the subcellular localization proved difficult, since little or no paucimannosidic epitopes could be detected in the analyzed compartments (ER, Golgi apparatus, Golgi-derived exocytic endosomes). This observation excludes a possible secretion via the conventional pathway of paucimannosidic proteins in line with recent findings, showing secretion of paucimannosidic proteins from activated neutrophils into sputum from pathogen-positive human lungs . A possible internalization of paucimannose-carrying proteins from the extracellular space was also excluded by the analysis of endocytic vesicles (Supplementary data, Figures S4 and S5) . N-glycome profiling using LC-MS/MS analysis confirmed higher levels of paucimannosidic structures, i.e. mannose 2 fucose 0-1 N-acetylglucosamine 2 (M2, M2F) and mannose 3-fucose 0-1 N-acetylglucosamine 2 (M3, M3F) in cell lysates compared with the microsomal fraction, indicating that paucimannosidic epitopes are predominantly carried by intracellular soluble proteins. Therefore, we hypothesize that the vesicle-like Mannitou staining in the cytoplasm may represent aggregates of paucimannosidic proteins within the cytoplasm. A possible mechanism of the transport of paucimannosidic proteins into the cytosol is not yet known but it may be speculated that they derive from the cis-Golgi compartment, since β1,2-N-acetylglucosamine proteins containing terminal β1,4-galactosylation or β1,4-bisecting N-acetylglucosaminylation which are derived from the trans-Golgi compartment are no HexA substrates . This aspect will be targeted in the future.
Significance of paucimannosylation
The presence of paucimannosidic glycoepitopes in NPCs is interesting, since they represent a highly promising avenue for the therapeutic intervention in relation to neurodegenerative diseases. Intensive research is being performed to identify cellular and molecular mechanisms regulating the differentiation and proliferation of neural stem cells. Further functional and structural experiments are needed to characterize the detailed role of paucimannosylation in postnatal NPCs. The proliferation-dependent expression of paucimannosidic epitopes in tumor cell lines (this study and Sethi et al. 2014) points to additional regulatory functions of paucimannosylation in tumor cells. Paucimannosidic proteins may show potential as a candidate diagnostic marker for tumor metastasis/aggressiveness.
In conclusion, paucimannosidic epitopes have recently been detected in several vertebrate cell types in physiological and pathophysiological conditions pointing to an important function of paucimannose in distinct tissues/conditions. We describe here the temporally regulated, specific expression of paucimannose in early postnatal NPCs in vivo and that show the expression of these novel vertebrate glycoepitopes is functionally linked to cell proliferation and differentiation.
Materials and methods
Generation of Mannitou, H28 and 123C3 antibody supernatants
Hybridoma cells producing Mannitou monoclonal mouse IgM antibody specifically recognizing the trimannosidic paucimannose structure M3 (Zipser et al. 2012) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium with 10% fetal calf serum and 100 U/mL penicillin and 100 µg/mL streptomycin. Hybridoma cells producing H28 antibody (monoclonal rat IgG anti-mouse neural cell adhesion molecule (NCAM) antibody, kindly provided by C. Goridis, Paris, France) or 123C3 antibody (monoclonal mouse anti-human NCAM antibody, kind gift of R. Michalides, Amsterdam, The Netherlands) were cultured in Dulbecco's Modified Eagle′s Medium (DMEM) with 10% fetal calf serum and 100 U/mL penicillin and 100 µg/mL streptomycin. For antibody production, hybridoma cells were cultured for 7 days, cell suspensions were then centrifuged at 2990 × g (4°C, 10 min) and supernatants were frozen for further applications. For injection into the LV, Mannitou and 123C3 supernatants were purified. Subsequently, purified antibody was concentrated to a final concentration of 500 ng/µL in sterile phosphate buffered saline (PBS) with 50 kDa molecular weight cut-off Amicon centrifugal filter devices (Millipore, Bedford, MA).
Cell culture
A172 cells (kind gift of Prof. Pietsch, University of Bonn, Germany) were cultured in DMEM with 10% fetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM additional L-glutamine. Thp-1 cells (kindly provided by Prof. Koch, University of Bonn, Germany) grew in RPMI 1640 medium containing 10% fetal calf serum and 100 U/mL penicillin and 100 µg/mL streptomycin. Cell proliferation of A172 and Thp-1 cells was inhibited by culturing the cells for 3 or 5 days in 2 or 10 µM AraC (Sigma-Aldrich, Taufkirchen, Germany), respectively. For the analysis of proliferation-dependent paucimannosylation, A172 cells were plated onto poly-L-lysine (pLL, 20 µg/mL) coated coverslips, whereas paucimannose expression in Thp-1 cells was analyzed in suspension.
For induction of differentiation, A172 and Thp-1 cells were plated onto pLL-coated coverslips (200 µg/mL). A172 cells were cultured in OptiMEM ® (Life Technologies, Carlsbad, CA) containing 1 mM dibutyryl cyclic AMP and 0.25 mM theophylline (both from SigmaAldrich) for 24 h. Thp-1 cells were differentiated in serum-free RPMI 1640 medium containing 200 nM 12-myristate 13-acetate (Sigma-Aldrich) for 24 h. To determine cell proliferation in the presence of Mannitou, A172 cells were plated onto pLL coated coverslips and incubated for 3 days with either a mixture of RPMI 1640/DMEM (1:1), H28 hybridoma DMEM supernatant/RPMI 1640 (1:1) or Mannitou hybridoma RPMI 1640 supernatant/DMEM (1:1). H28 antibody specifically detects mouse neural cell adhesion molecule NCAM but has no reactivity in human cells. Cells were then subjected to immunofluorescence analysis.
Quantitative immunofluorescence analysis and subcellular localization of paucimannosidic epitopes
For analysis of paucimannose expression, A172 or Thp-1 cells were cultured for 3 days and fixed with 4% formaldehyde followed by blocking and permeabilization with 5% horse serum in PBS/0.5% Triton X-100 for 20 min at room temperature. For analysis of cell surface paucimannose, cells were fixed with 4% paraformaldehyde without permeabilization followed by blocking solution in 5% horse serum in PBS. Cells were incubated with undiluted Mannitou supernatant for 30 min at room temperature before incubation with antimouse IgM Cy2-conjugated secondary antibodies (1:500, Dianova, Hamburg, Germany).
Intracellular localization of paucimannosidic epitopes in A172 cells was investigated by co-staining cells with Mannitou and markers staining specific subcellular components: to analyze lysosomal localization, cells were cultured in the presence of 200 nM LysoTracker Red (Life Technologies) for 30 min directly before immunofluorescence analysis. Analysis of ER or Golgi localization of paucimannose was performed using following rabbit IgG antibodies: anti-protein disulfide isomerase and anti-ER stress protein 72 antibodies as ER markers; anti-receptor binding cancer antigen expressed on SiSo cells antibody and anti-syntaxin 6 antibody as trans-Golgi and endosome markers (all from NEB Cell Signaling Technology, Frankfurt, Germany, concentration of 1:100, respectively). For co-localization of paucimannose and HexA, cells were fixed, permeabilized and incubated with Mannitou and rabbit IgG anti-HexA antibodies (1:200, Santa Cruz, Heidelberg, Germany). Antigenes were visualized using anti-mouse IgM Cy2-and anti-rabbit IgG Cy3-conjugated secondary antibodies (both 1:500, Dianova).
Potential localization of paucimannosidic epitopes in early endosomes and recycling vesicles was detected by co-localization of Mannitou with GFP-Rab5, GFP-Rab4 or GFP-Rab11 proteins. For this purpose, A172 cells were plated onto pLL-coated coverslips and transfected 24 h later with either of the GFP-Rab-cDNA constructs using Turbofect according to the manufacturer's recommendations (Thermo Scientific, Schwerte, Germany). Cells were incubated 2 more days, immunofluorescence analysis using Mannitou was then performed by fixation and permeabilization of the cells and paucimannose was visualized using anti-mouse Cy3-conjugated secondary antibodies.
Cell proliferation was analyzed by culturing A172 cells for 3 days in respective supernatants. Cells were then fixed, permeabilized and incubated with rabbit IgG anti-Ki67 antibodies (Abcam, Cambridge, UK) in a concentration of 1:200 in blocking solution followed by incubation with anti-rabbit Cy3-conjugated secondary antibodies for 30 min.
For analysis of Mannitou fate after incubation for 3 days in cell culture medium, cells were fixed with 4% formaldehyde and permeabilized. As a control, cells were cultured without Mannitou in the same medium. For analysis of proliferating cells, an additional incubation with anti-Ki67 antibody was performed. Subsequently, cells were incubated with anti-mouse Cy2-conjugated antibody to visualize Mannitou and anti-rabbit Cy3-conjugated antibodies for detection of Ki67 (both 1:500, respectively).
In some experiments, cell nuclei were stained with Hoechst 33258 (Sigma-Aldrich) and cells were then embedded in Permafluor (Thermo Scientific). Paucimannose glycoepitopes were analyzed by taking pictures using a fluorescence microscope (Axioplan2, ApoTome system, Zeiss, Oberkochen, Germany) with a Plan Apochromat 20×/0.75 objective. Fluorescence intensity per cell was determined by manually outlining paucimannose-positive cells in Image J software (NIH). Mean fluorescence intensity in pixel was determined in the selected region and the background was subtracted. Co-localization was determined by analyzing pictures taken with a Zeiss LSM510 MetaUV confocal microscope equipped with a Plan Apochromat 63×/1.40 oil immersion objective (Zeiss).
Cell viability assay
For analysis of cell viability, cells were plated and treated with Mannitou as described in the "cell culture" section. As a control for the functionality of the assay, cells were treated with 70% methanol for 25 min to induce cell death. The cell viability was measured as described in the manufacturer's instructions (BioCat, Heidelberg, Germany) using Calcein AM/Ethidium Homodimer solution or MTT assay, respectively. Calcein AM and Ethidium Homodimer were analyzed by taking pictures using a fluorescence microscope equipped with a Plan Apochromat 20×/0.75 objective. The colored MTT formazan product produced by living cells was detected colorimetrically using an enzyme-linked immunosorbent assay reader (Titertek PLUS MS2, ICN, Meckenheim, Germany) at 550 nm.
Generation of cell lysates and microsomal fractions for glycomics profiling A172 cells were cultured as described in the "cell culture" section and treated with 10 µM AraC for 3 days. Cell lysates were generated using RIPA lysis buffer (c.c.pro, Oberdorla, Germany) and centrifugation at 20,000 × g (4°C). Cleared cell lysates were subjected to acetone precipitation.
Microsomal (total membrane) fractions were obtained by harvesting cells in 25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid containing leupeptin, pepstatin A, aprotinin and phenylmethanesulfonylfluoride. The cells were ultra-sonicated on ice for six rounds of 10-s bursts using a Sonifier 250 (Branson Ultrasonics, Danbury) followed by centrifugation at 2000 × g for 20 min (4°C) to remove intact cells and nuclei. The supernatants were ultracentrifuged at 120,000 × g for 80 min (4°C). The microsomal membrane pellets were washed twice with ice-cold 0.1 M sodium carbonate and resuspended in 25 mM Tris-HCl, pH 7.4, 150 mM NaCl and 1% (v/v) Triton X-114. Samples were subjected to phase partitioning by incubation at 37°C for 20 min, followed by 1000 × g centrifugation for 10 min. The upper aqueous layer was carefully removed and proteins in the lower detergent phase were acetone precipitated. The pellets were dissolved in 8 M urea and subjected to glycomics profiling.
Cell lysates and microsomal fractions were generated in triplicate. Protein concentrations were determined prior to acetone precipitations using the Biorad D c protein assay (München, Germany).
Release and preparation of N-glycans from cell lysates and microsomal proteins N-Glycans were released from ∼10 µg of cell lysate and microsomal membrane proteins as described previously (Jensen et al. 2012) . In brief, proteins were immobilized on polyvinylidene difluoride membrane (Millipore, Kilsyth, Australia) and the N-glycans of bound proteins were released by incubation with 5 U N-glycosidase F (Flavobacterium meningosepticum, Roche, Castle Hill, Australia) for 16 h at 37°C. Released N-glycans were incubated with 100 mM ammonium acetate ( pH 5) for 1 h at room temperature and dried by vacuum centrifugation. Reduction in N-glycans was performed with 1 M sodium borohydride in 50 mM potassium hydroxide for 3 h at 50°C, followed by glacial acetic acid quenching. Desalting of N-glycans was performed in micro-solid phase extraction formats using strong cation exchange/C18 and carbon columns and elution was performed with 40% (v/v) acetonitrile containing 0.1% (v/v) trifluoroacetic acid and dried by vacuum centrifugation.
LC-MS/MS-based N-glycomics
N-Glycans were analyzed by capillary LC-MS/MS (Agilent 1260 Infinity) using an electrospray ionization-ion trap mass spectrometer (LC/MSD Trap XCT Plus Series 1100, Agilent Technologies, Mulgrave, Australia). Samples were injected onto a porous graphitized carbon capillary column (3 µm Hypercarb KAPPA, 180 µm × 100 mm, Thermo Hypersil Scoresby, Australia) and separation of N-glycans was carried out over a linear gradient of 0-45% (v/v) acetonitrile/10 mM ammonium bicarbonate for 85 min at a flow rate of 2 µL/min. The sample injection volume was 5 µL. MS acquisition were m/z 200-2200 range in negative ionization mode, and top two most abundant precursors in each spectrum were selected for MS/ MS using collision-induced dissociation. Mass accuracy calibration of the mass spectrometer was performed using a well-defined tune mix (Agilent) prior to acquisition. MS and MS/MS data were analyzed and quantified using Compass Data Analysis v4.0 software (Bruker Daltonics, Preston, Australia) as described previously (Sethi et al. 2014) .
Immunohistochemistry
For histological analysis, P0, P2, P4, P7 or P10 old pups of CD1 mice (Charles River, Sulzfeld, Germany) were deeply anesthetized with an overdose of ketamine/xylazin (100 mg and 5 mg/kg body weight, respectively). Perfusion was performed intracardially with a solution of 2% paraformaldehyde in PBS. The brains were dissected out and immersed overnight in the same fixative at 4°C. Coronal sections were cut at 60 µm using a microtome (Microm, Walldorf, Germany). Immunohistochemistry was carried out on floating vibratome sections. Sections were first blocked with 5% horse serum in PBS/0.5% Triton X-100 for 1 h at room temperature followed by incubation with undiluted Mannitou supernatant overnight at 4°C. After three washing steps in 5% horse serum/PBS incubation with labeled secondary antibodies followed for 1 h. Before mounting, cell nuclei were stained with Hoechst 33258.
As control, some slices were incubated with Mannitou that was preincubated with 0.5 M α-methyl mannoside for 8 h at room temperature to abolish binding of Mannitou to cellular paucimannosidic glycoepitopes. As a secondary antibody control, some slices were incubated with blocking solution (5% horse serum in PBS) instead of Mannitou.
Images were taken using a fluorescence microscope (Axioplan2, ApoTome system; Zeiss) with an A-Plan 10×/0.25 objective.
Intraventricular injection/electroporation of Mannitou/ eGFP plasmid Animals were treated and experiments were carried out according to guidelines approved by the German ethical committee and the European Communities Council Directive (24 November 1986, 86/609/ EEC). Intraventricular injection/electroporation was performed as described in Boutin et al. (2008) . Briefly, 1-day-old pups of CD1 mice were anesthetized by hypothermia (4 min). Mice were fixed to a support and co-injection into the LV was performed using a mixture of 5 µg pCX-eGFPN1-plasmid [described in Morin et al. 2007 , concentration 5 µg/µL prepared using an EndoFree Plasmid Kit (Qiagen, Hilden, Germany)] and 500 ng purified Mannitou in PBS. As a negative control, a mixture of pCX-eGFP-N1 plasmid and 500 ng 123C3 antibody was used. 123C3 antibody specifically detects human NCAM and has therefore no reactivity in mouse brain. Successfully injected animals were subjected to five electrical pulses (100 V, 50 ms, separated by 950 ms intervals) using the CUY21 edit device (Nepagene, Chiba, Japan) and 10-mm tweezer electrodes (CUY650P10; Nepagene). Directly after the electroporation pups received, the analgetic drug carprofen (5 mg/kg body weight subcutaneously) and after reanimation animals were returned to the mother. Mice were analyzed 2 days after electroporation. Brains were perfused and sectioned as described in the section "immunohistochemistry", stained with Hoechst 33258 and mounted on slides for microscopy analysis of eGFP-positive cells.
Statistical analysis
Statistical analysis was calculated from at least three independent experiments. Two groups were analyzed using the unpaired t-test, whereas three or more groups were analyzed by one-way analysis of variance followed by the Tukey's post hoc test. Data are presented as the mean ± SEM or SD as indicated in the figure legend. P-values of <0.05 were considered statistically significant (*P < 0.05, **P < 0.005, ***P < 0.001).
Supplementary data
Supplementary data for this article is available online at http://glycob. oxfordjournals.org/. 
